Stock CLXPFCYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:46:07 2025-04-17 pm EDT 		5-day change 1st Jan Change
7.315 USD -1.81% Intraday chart for Cybin Inc. +28.20% -16.57%
Feb. 10 Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
Jan. 15 Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment MT

Press Releases

Search
See the results
Cybin : Corporate Presentation February 2025
Feb. 11
 PU
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Feb. 10
 BU
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Jan. 15
 BU
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Jan. 13
 BU
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Jan. 09
 BU
Cybin : Corporate Presentation December 2024
Dec. 10
 PU
Cybin : Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12 Month Efficacy Results Form 6 K
Dec. 10
 PU
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Dec. 10
 BU
Cybin : to Participate in Water Tower Research Fireside Chat on December 11, 2024 Form 6 K
Dec. 04
 PU
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Dec. 04
 BU
Cybin : Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12 Month Efficacy in Treating Major Depressive Disorder Form 6 K
Nov. 18
 PU
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Nov. 18
 BU
Cybin : to Present 12 Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 Form 6 K
Nov. 14
 PU
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Nov. 14
 BU
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Nov. 13
 BU
Cybin : to Participate at the 2024 Milken Institute Future of Health Summit Form 6 K
Nov. 01
 PU
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
24-10-31
 BU
Cybin : Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program Form 6 K
24-10-24
 PU
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
24-10-24
 BU
Cybin : to Participate in Water Tower Research Fireside Chat on October 8, 2024 Form 6 K
24-10-03
 PU
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
24-10-03
 BU
Cybin : Expands Clinical Team to Support CYB003 Phase 3 Program Form 6 K
24-10-01
 PU
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
24-10-01
 BU
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
24-09-24
 BU
Cybin Provides Corporate Update on Upcoming Clinical Milestones
24-09-19
 BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLXPF Stock
  4. News Cybin Inc.
  5. Press Releases